PTGS2 and breast cancer: We hypothesized that the SERM Ly117018 and the COX-2 inhibitor celecoxib synergistically inhibit cell proliferation of ER-positive MCF-7 and ER-negative MDA-MB-435 human breast cancer cells in vitro.